Fig. 4From: Cost-effectiveness and budget impact analysis of lisdexamfetamine versus methylphenidate for patients under 18 with attention-deficit/hyperactivity disorder in IranCost-effectiveness accessibility curve of LDX vs. MPH for estimating the willingness to pay for LDX in treating ADHD for patients under 18 years old in Iran (Monte Carlo simulation)Back to article page